94 patents
Utility
Compositions and methods for detecting protease activity in biological systems
9 Jan 24
The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.
Olga Vasiljeva, Elizabeth-Edna Mary Menendez
Filed: 30 Apr 21
Utility
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
2 Jan 24
Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs).
Leila Marie Boustany, Sherry L. La Porte, Bryan A. Irving, Jeanne Grace Flandez
Filed: 7 Sep 22
Utility
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
14 Nov 23
The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.
Stephen James Moore, Margaret Thy Luu Nguyen, Daniel R. Hostetter, Olga Vasiljeva, Jeanne Grace Flandez
Filed: 2 Nov 18
Utility
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
31 Oct 23
The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson
Filed: 24 Apr 20
Utility
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
12 Sep 23
The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
Filed: 20 Dec 19
Utility
Matrix Metalloprotease-cleavable and Serine Protease-cleavable Substrates and Methods of Use Thereof
6 Jul 23
The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST
Filed: 7 Dec 22
Utility
ANTI-SLC34A2 Antibodies, Antibody Drug Conjugates, and Methods of Use Thereof
9 Mar 23
The invention relates generally to antibodies that bind SLC34A2, and methods of making and using these anti-SLC34A2 antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Dowdy Jackson, Yuriy Shostak, Christopher Kemball, Pia Challita-Eid
Filed: 6 Jan 21
Utility
Auristatin-related Compounds, Conjugated Auristatin-related Compounds, and Methods of Use Thereof
9 Mar 23
The invention relates generally to novel compounds of the auristatin family, to novel linkers for coupling a payload to another molecule, such a target-binding molecule, to novel linker-toxin molecules, and to novel antibody molecules that allow controlled, site-specific conjugation.
Siew Schleyer, Brian A. Mendelsohn, Pia Challita-Eid, Dowdy Jackson, Christopher Kemball
Filed: 6 Jan 21
Utility
Single-and Multi-chain Polypeptides That Bind Specifically to CD3 Epsilon
23 Feb 23
Provided herein are single-chain polypeptides and multi-chain polypeptides that bind specifically to CD3 epsilon (CD3ε).
Christopher KEMBALL, Pia CHALLITA-EID, Rene HUBERT
Filed: 6 Jan 21
Utility
Anti-psma Antibodies, Antibody Drug Conjugates, and Methods of Use Thereof
23 Feb 23
The invention relates generally to antibodies that bind PSMA, and methods of making and using these anti-PSMA antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Rene Hubert, Christopher Kemball, Pia Challita-Eid
Filed: 6 Jan 21
Utility
Antibodies, Activatable Antibodies, Bispecific Antibodies, and Bispecific Activatable Antibodies and Methods of Use Thereof
16 Feb 23
Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs).
Leila Marie BOUSTANY, Sherry L. LA PORTE, Bryan A. IRVING, Jeanne Grace FLANDEZ
Filed: 7 Sep 22
Utility
Proproteins and Methods of Use Thereof
2 Feb 23
The present disclosure provides for proprotein and activatable proprotein compositions.
Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G. Sagert
Filed: 21 Mar 22
Utility
CorrectedMatrix Metalloprotease-cleavable and Serine Protease-cleavable Substrates and Methods of Use Thereof
19 Jan 23
The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST
Filed: 28 Jun 21
Utility
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
10 Jan 23
The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
Filed: 28 Jun 21
Utility
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
10 Jan 23
The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
Filed: 28 Jun 21
Utility
Matriptase and U-plasminogen Activator Substrates and Other Cleavable Moieties and Methos of Use Thereof
29 Dec 22
The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.
Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA
Filed: 26 Apr 21
Utility
Activatable Cytokine Constructs and Related Compositions and Methods
22 Dec 22
Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.
Sayantan Mitra, Nicole G. Lapuyade, Hikmat Haizar Assi, Madan M. Paidhungat, Dylan L. Daniel, Erwan Le Scolan, Walter A. Bogdanoff, Na Cai, Hsin WANG
Filed: 25 May 22
Utility
CorrectedMatrix Metalloprotease-cleavable and Serine Protease-cleavable Substrates and Methods of Use Thereof
1 Dec 22
The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST
Filed: 28 Jun 21
Utility
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
18 Oct 22
The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
Filed: 28 Jun 21
Utility
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
18 Oct 22
Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs).
Leila Marie Boustany, Sherry L. La Porte, Bryan A. Irving, Jeanne Grace Flandez
Filed: 12 Oct 18